Development of replication-competent viral vectors for HIV vaccine delivery

Current Opinion in HIV and AIDS

Volumn 8, Issue 5, 2013, Pages 402-411

  Parks, Christopher L ^a   Picker, Louis J ^b,c   King, C Richter ^a  

^a INTERNATIONAL AIDS VACCINE INITIATIVE   (United States)

^b Vaccine and Gene Therapy Institute   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

HIV vaccine; replication competent viral vectors; SIV challenge model

Indexed keywords

ADENOVIRUS VECTOR; CONDITIONALLY REPLICATING ADENOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; REPLICATION COMPETENT VIRAL VECTOR; UNCLASSIFIED DRUG; VIRUS VECTOR;

CANINE DISTEMPER MORBILLIVIRUS; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS; DNA VIRUS; DRUG DELIVERY DEVICE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOGENICITY; MEASLES VIRUS; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; RABIES VIRUS; REVIEW; RHADINOVIRUS; RNA VIRUS; SAFETY; SEMLIKI FOREST ALPHAVIRUS; SENDAI VIRUS; SIMIAN IMMUNODEFICIENCY VIRUS; TECHNOLOGY; VACCINIA VIRUS; VENEZUELAN EQUINE ENCEPHALOMYELITIS ALPHAVIRUS; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; YELLOW FEVER FLAVIVIRUS;

EID: 84883400877     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328363d389     Document Type: Review

References (122)

1. Montagnier L. 25 years after HIV discovery: prospects for cure and vaccine. Virology 2010; 397:248-254.
2. Gallo RC. A reflection on HIV/AIDS research after 25 years. Retrovirology 2006; 3:72.
3. Girard MP, Koff WC. Human immunodeficiency virus vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines. Philadelphia: Elsevier Saunders; 2012. pp. 1097-1121.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
5. Girard MP, Plotkin SA. HIV vaccine development at the turn of the 21st century. Curr Opin HIV AIDS 2012; 7:4-9.
6. Meeusen EN, Walker J, Peters A, et al. Current status of veterinary vaccines. Clin Microbiol Rev 2007; 20:489-510.
7. Plotkin SL, Plotkin SA. A short history of vaccination. In: Plotkin SA, Orenstein WA, Offit PA, editors. Vaccines, 6 edition Philadelphia: Elsevier Saunders; 2012. pp. 1-13.
8. Plotkin SA. Complex correlates of protection after vaccination. Clin Infect Dis 2013.
9. Koff WC, Johnson PR, Watkins DI, et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 2006; 7:19-23.
10. Baba TW, Liska V, Khimani AH, et al. Live attenuated, multiply deleted simian immunodeficiency virus causes AIDS in infant and adult macaques. Nat Med 1999; 5:194-203.
11. Duerr A, Wasserheit JN, Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006; 43:500-511.
12. Learmont J, Cook L, Dunckley H, et al. Update on long-term symptomless HIV type 1 infection in recipients of blood products from a single donor. AIDS Res Hum Retroviruses 1995; 11:1.
13. Learmont J, Tindall B, Evans L, et al. Long-term symptomless HIV-1 infection in recipients of blood products from a single donor. Lancet 1992; 340:863-867.
14. Whitney JB, Ruprecht RM. Live attenuated HIV vaccines: pitfalls and prospects. Curr Opin Infect Dis 2004; 17:17-26.
15. Querec TD, Akondy RS, Lee EK, et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009; 10:116-125.
16. Gaucher D, Therrien R, Kettaf N, et al. Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses. J Exp Med 2008; 205:3119-3131.
17. Nakaya HI, Pulendran B. Systems vaccinology: its promise and challenge for HIV vaccine development. Curr Opin HIV AIDS 2012; 7:24-31.
18. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011; 62:127-139.
19. Fukazawa Y, Park H, Cameron MJ, et al. Lymph node T cell responses predict the efficacy of live attenuated SIV vaccines. Nat Med 2012; 18:1673-1681.
20. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006; 24:1377-1383.
21. Guy B, Guirakhoo F, Barban V, et al. Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 2010; 28:632-649.
22. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010; 8:62-73.
23. Koff WC, Parks CL, Berkhout B, et al. Replicating viral vectors as HIV vaccines Summary Report from IAVI Sponsored Satellite Symposium, International AIDS Society Conference July 22 2007. Biologicals 2008; 36:277-286.
24. Robert-Guroff M. Replicating and nonreplicating viral vectors for vaccine development. Curr Opin Biotechnol 2007; 18:546-556.
25. Patterson LJ, Robert-Guroff M. Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development. Expert Opin Biol Ther 2008; 8:1347-1363.
26. Liniger M, Zuniga A, Naim HY. Use of viral vectors for the development of vaccines. Expert Rev Vaccines 2007; 6:255-266.
27. Li S, Locke E, Bruder J, et al. Viral vectors for malaria vaccine development. Vaccine 2007; 25:2567-2574.
28. Excler JL, Parks CL, Ackland J, et al. Replicating viral vectors as HIV vaccines: summary report from the IAVI-sponsored satellite symposium at the AIDS vaccine 2009 conference. Biologicals 2010; 38:511-521.
29. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. Annu Rev Med 2012; 63:95-111.
30. Clarke DK, Cooper D, Egan MA, et al. Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector. Springer Semin Immunopathol 2006; 28:239-253.
31. Gurwith M, Lock M, Taylor EM, et al. Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study. Lancet Infect Dis 2013; 13:238-250.
32. Patterson LJ, Kuate S, Daltabuit-Test M, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) vectors efficiently prime SIV-specific systemic and mucosal immune responses by targeting myeloid dendritic cells and persisting in rectal macrophages, regardless of immunization route. Clin Vaccine Immunol 2012; 19:629-637.
33. Xiao P, Patterson LJ, Kuate S, et al. Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge. J Virol 2012; 86:4644-4657.
34. Abbink P, Maxfield LF, Barouch DH. Development of replication-competent adenovirus based vaccine vectors. Retrovirology 2012; 9 (suppl. 2):P310.
35. Handley SA, Thackray LB, Zhao G, et al. Pathogenic simian immunodeficiency virus infection is associated with expansion of the enteric virome. Cell 2012; 151:253-266.
36. Hansen SG, Ford JC, Lewis MS, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 2011; 473:523-527.
37. Hansen SG, Vieville C, Whizin N, et al. Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med 2009; 15:293-299.
38. Murphy CG, Lucas WT, Means RE, et al. Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus. J Virol 2000; 74:7745-7754.
39. Bilello JP, Manrique JM, Shin YC, et al. Vaccine protection against simian immunodeficiency virus in monkeys using recombinant gamma-2 herpesvirus. J Virol 2011; 85:12708-12720.
40. Willer DO, Ambagala AP, Pilon R, et al. Experimental infection of Cynomolgus Macaques (Macaca fascicularis) with human varicella-zoster virus. J Virol 2012; 86:3626-3634.
41. Shao Y, Li T, Wolf H, et al. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia virus vector in phase 1 clinical trial. In AIDS Vaccine 2009, vol. 6, P404. Paris, France: Retrovirology.
42. Kibler KV, Gomez CE, Perdiguero B, et al. Improved NYVAC-based vaccine vectors. PLoS One 2011; 6:e25674.
43. Quakkelaar ED, Redeker A, Haddad EK, et al. Improved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectors. PLoS One 2011; 6:e16819.
44. Dai K, Liu Y, Liu M, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008; 26:5062-5071.
45. Zhu R, Huang W, Wang W, et al. Comparison on virulence and immunogenicity of two recombinant vaccinia vaccines, Tian Tan and Guang9 strains, expressing the HIV-1 envelope gene. PLoS One 2012; 7: e48343.
46. Zhang X, Sobue T, Isshiki M, et al. Elicitation of both anti HIV-1 Env humoral and cellular immunities by replicating vaccinia prime Sendai virus boost regimen and boosting by CD40Lm. PLoS One 2012; 7:e51633.
47. Zhang X, Richlak S, Nguyen HT, et al. Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors. Retrovirology 2012; 9 (suppl. 2):298.
48. Reece JC, Alcantara S, Gooneratne S, et al. Trivalent live attenuated Influenza-SIV vaccines: efficacy and evolution of CTL escape in macaques. J Virol 2013; 87:4146-4160.
49. Stebbings R, Fevrier M, Li B, et al. Immunogenicity of a recombinant measles-HIV-1 clade B candidate vaccine. PLoS One 2012; 7:e50397.
50. Lorin C, Segal L, Mols J, et al. Toxicology, biodistribution and shedding profile of a recombinant measles vaccine vector expressing HIV-1 antigens, in cynomolgus macaques. Naunyn Schmiedebergs Arch Pharmacol 2012; 385:1211-1225.
51. Mourez T, Mesel-Lemoine M, Combredet C, et al. A chimeric measles virus with a lentiviral envelope replicates exclusively in CD4\+/CCR5\+ cells. Virology 2011; 419:117-125.
52. Xu R, Nasar F, Megati S, et al. Prime-boost vaccination with recombinant mumps virus and recombinant vesicular stomatitis virus vectors elicits an enhanced human immunodeficiency virus type 1 Gag-specific cellular immune response in rhesus macaques. J Virol 2009; 83:9813-9823.
53. Khattar SK, Samal S, Devico AL, et al. Newcastle disease virus expressing human immunodeficiency virus type 1 envelope glycoprotein induces strong mucosal and serum antibody responses in Guinea pigs. J Virol 2011; 85:10529-10541.
54. Maamary J, Array F, Gao Q, et al. Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice. J Virol 2011; 85:2235-2246.
55. Carnero E, Li W, Borderia AV, et al. Optimization of human immunodeficiency virus gag expression by newcastle disease virus vectors for the induction of potent immune responses. J Virol 2009; 83:584-597.
56. McKenna PM, Koser ML, Carlson KR, et al. Highly attenuated rabies virusbased vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease. J Infect Dis 2007; 195:980-988.
57. Faul EJ, Aye PP, Papaneri AB, et al. Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8\+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge. Vaccine 2009; 28:299-308.
58. Matano T, Kobayashi M, Igarashi H, et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J Exp Med 2004; 199:1709-1718.
59. Kawada M, Tsukamoto T, Yamamoto H, et al. Long-term control of simian immunodeficiency virus replication with central memory CD4\+ T-cell preservation after nonsterile protection by a cytotoxic T-lymphocyte-based vaccine. J Virol 2007; 81:5202-5211.
60. Rose NF, Roberts A, Buonocore L, et al. Glycoprotein exchange vectors based on vesicular stomatitis virus allow effective boosting and generation of neutralizing antibodies to a primary isolate of human immunodeficiency virus type 1. J Virol 2000; 74:10903-10910.
61. Rose NF, Marx PA, Luckay A, et al. An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell 2001; 106:539-549.
62. Cooper D, Wright KJ, Calderon PC, et al. Attenuation of recombinant vesicular stomatitis virus-human immunodeficiency virus type 1 vaccine vectors by gene translocations and g gene truncation reduces neurovirulence and enhances immunogenicity in mice. J Virol 2008; 82:207-219.
63. Johnson JE, Coleman JW, Kalyan NK, et al. In vivo biodistribution of a highly attenuated recombinant vesicular stomatitis virus expressing HIV-1 Gag following intramuscular, intranasal, or intravenous inoculation. Vaccine 2009; 27:2930-2939.
64. Jurgens CK, Morrow G, Boggiano C, et al. Evaluation of a replicationcompetent VSV-SIV vaccine candidate. Retrovirology 2012; 9:329.
65. Johnson JE, Schnell MJ, Buonocore L, et al. Specific targeting to CD4\+ cells of recombinant vesicular stomatitis viruses encoding human immunodeficiency virus envelope proteins. J Virol 1997; 71:5060-5068.
66. Gu R, Stagnar C, Zaichenko L, et al. Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants. Vaccine 2012; 30:3666-3674.
67. Crotty S, Andino R. Poliovirus vaccine strains as mucosal vaccine vectors and their potential use to develop an AIDS vaccine. Adv Drug Deliv Rev 2004; 56:835-852.
68. Crotty S, Miller CJ, Lohman BL, et al. Protection against simian immunodeficiency virus vaginal challenge by using Sabin poliovirus vectors. J Virol 2001; 75:7435-7452.
69. Virnik K, Ni Y, Berkower I. Live attenuated rubella viral vectors stably express HIV and SIV vaccine antigens while reaching high titers. Vaccine 2012; 30:5453-5458.
70. Rose NF, Publicover J, Chattopadhyay A, et al. Hybrid alphavirus-rhabdovirus propagating replicon particles are versatile and potent vaccine vectors. Proc Natl Acad Sci USA 2008; 105:5839-5843.
71. Schell JB, Rose NF, Bahl K, et al. Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen. J Virol 2011; 85:5764-5772.
72. Martins MA, Bonaldo MC, Rudersdorf RA, et al. Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques. PLoS One 2013; 8:e54434.
73. Bonaldo MC, Martins MA, Rudersdorf R, et al. Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8\+ T-cell responses in rhesus macaques. J Virol 2010; 84:3699-3706.
74. Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 2005; 16:149-156.
75. Tatsis N, Ertl HC. Adenoviruses as vaccine vectors. Mol Ther 2004; 10:616-629.
76. Hoke CH Jr, Snyder CE Jr. History of the restoration of adenovirus type 4 and type 7 vaccine, live oral (Adenovirus Vaccine) in the context of the Department of Defense acquisition system. Vaccine 2013; 31:1632-1632.
77. Alexander J,Gurwith M, Mendy J, et al. Development of a HIV-1 vaccine using an orally-administered, replication-competent adenovirus serotype 4 vector expressing Env clade C glycoprotein. In AIDS Vaccine 2012, vol. 9, P35. Boston, Massachusetts USA: Retrovirology.
78. O'Hara GA, Duncan CJ, Ewer KJ, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012; 205:772-781.
79. Borthwick NJ, Ahmed T, Rose A, et al. Immunogenicity of a universal HIV-1 vaccine vectored by DNA, MVA and CHADV-63 in a Phase I/IIA clinical trial. Retrovirology 2012; 9(suppl. 2):P118.
80. Mocarski ES, Shenk T, Pass RF. Cytomegaloviruses. In: Knipe DM, Howley PM, editors. Fields Virology. Volume 2, 5th edition Philadelphia: Lippincott Williams and Wilkins; 2007. pp. 2701-2772.
81. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008; 325:417-470.
82. Murphy E, Shenk T. Human cytomegalovirus genome. Curr Top Microbiol Immunol 2008; 325:1-19.
83. Malouli D, Nakayasu ES, Viswanathan K, et al. Reevaluation of the coding potential and proteomic analysis of the BAC-derived rhesus cytomegalovirus strain 68-1. J Virol 2012; 86:8959-8973.
84. Davison AJ, Dolan A, Akter P, et al. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J Gen Virol 2003; 84:17-28.
85. Pereira L, Maidji E. Cytomegalovirus infection in the human placenta: maternal immunity and developmentally regulated receptors on trophoblasts converge. Curr Top Microbiol Immunol 2008; 325:383-395.
86. Pantaleo G, Esteban M, Jacobs B, et al. Poxvirus vector-based HIV vaccines. Curr Opin HIV AIDS 2010; 5:391-396.
87. Zhang Q, Tian M, Feng Y, et al. Genomic sequence and virulence of clonal isolates of vaccinia virus tiantan, the chinese smallpox vaccine strain. PLoS One 2013; 8:e60557.
88. Sun C, Chen Z, Tang X, et al. Mucosal prime with a replicating vacciniabased vaccine elicits protective immunity against SIV challenge in rhesus monkeys. J Virol 2013; 87:5669-5677.
89. Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors-NYVAC and ALVAC. Dev Biol Stand 1994; 82:65-69.
90. Conzelmann KK. Reverse genetics of mononegavirales. Curr Top Microbiol Immunol 2004; 283:1-41.
91. Neumann G, Whitt MA, Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA-what have we learned? J Gen Virol 2002; 83:2635-2662.
92. Fuchs JD, Frank I, Kochar N, et al. First-in-human phase 1 clinical trial of a recombinant vesicular stomatitis virus (rVSV)-based preventative vaccine. Retrovirology 2012; 9(suppl. 2):P134.
93. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-Poisson distribution of transmitted variants. J Virol 2009; 83:3556-3567.
94. Marthas ML, Van Rompay KK, Abbott Z, et al. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 2011; 29:3124-3137.
95. Van Rompay KK, Abel K, Earl P, et al. Immunogenicity of viral vector, primeboost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 2010; 28:1481-1492.
96. Schell J, Rose NF, Fazo N, et al. Long-term vaccine protection from AIDS and clearance of viral DNA following SHIV89.6P challenge. Vaccine 2009; 27:979-986.
97. Egan MA, Chong SY, Megati S, et al. Priming with plasmid DNAs expressing interleukin-12 and simian immunodeficiency virus gag enhances the immunogenicity and efficacy of an experimental AIDS vaccine based on recombinant vesicular stomatitis virus. AIDS Res Hum Retroviruses 2005; 21:629-643.
98. Geisbert TW, Feldmann H. Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections. J Infect Dis 2011; 204 (Suppl 3):S1075-S1081.
99. Gunther S, Feldmann H, Geisbert TW, et al. Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 2011; 204 (Suppl 3):S785-790.
100. Faisca P, Desmecht D. Sendai virus, the mouse parainfluenza type 1: a longstanding pathogen that remains up-to-date. Res Vet Sci 2007; 82:115-125.
101. Hara H, Hara H, Hironaka T, et al. Prevalence of specific neutralizing antibodies against Sendai virus in populations from different geographic areas: implications for AIDS vaccine development using Sendai virus vectors. Hum Vaccin 2011; 7:639-645.
102. Moriya C, Horiba S, Kurihara K, et al. Intranasal Sendai viral vector vaccination is more immunogenic than intramuscular under preexisting antivector antibodies. Vaccine 2011; 29:8557-8563.
103. de Vries RD, Lemon K, Ludlow M, et al. In vivo tropism of attenuated and pathogenic measles virus expressing green fluorescent protein in macaques. J Virol 2010; 84:4714-4724.
104. von Messling V, Milosevic D, Cattaneo R. Tropism illuminated: lymphocytebased pathways blazed by lethal morbillivirus through the host immune system. Proc Natl Acad Sci USA 2004; 101:14216-14221.
105. Lin WH, Kouyos RD, Adams RJ, et al. Prolonged persistence of measles virus RNA is characteristic of primary infection dynamics. Proc Natl Acad Sci USA 2012; 109:14989-14994.
106. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-1042.
107. Dine MS, Hutchins SS, Thomas A, et al. Persistence of vaccine-induced antibody to measles 26-33 years after vaccination. J Infect Dis 2004; 189 (Suppl 1):S123-130.
108. Croyle MA, Patel A, Tran KN, et al. Nasal delivery of an adenovirus-based vaccine bypasses preexisting immunity to the vaccine carrier and improves the immune response in mice. PLoS One 2008; 3:e3548.
109. Knuchel MC, Marty RR, Morin TN, et al. Relevance of a preexisting measles immunity prior immunization with a recombinant measles virus vector. Hum Vaccin Immunother 2013; 9.
110. Miest TS, Yaiw KC, Frenzke M, et al. Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 2011; 19:1813-1820.
111. Hudacek AW, Navaratnarajah CK, Cattaneo R. Development of measles virus-based shielded oncolytic vectors: suitability of other paramyxovirus glycoproteins. Cancer Gene Ther 2013; 20:109-116.
112. Rima BK, Duprex WP. Morbilliviruses and human disease. J Pathol 2006; 208:199-214.
113. Rayner JO, Dryga SA, Kamrud KI. Alphavirus vectors and vaccination. Rev Med Virol 2002; 12:279-296.
114. Monath TP. Yellow fever vaccine. Expert Rev Vaccines 2005; 4:553-574.
115. Seino KK, Long MT, Gibbs EP, et al. Comparative efficacies of three commercially available vaccines against West Nile Virus (WNV) in a short-duration challenge trial involving an equine WNV encephalitis model. Clin Vaccine Immunol 2007; 14:1465-1471.
116. Halstead SB, Thomas SJ. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev Vaccines 2011; 10:355-364.
117. Jurgens CK, Young KR, Madden VJ, et al. A novel self-replicating chimeric lentivirus-like particle. J Virol 2012; 86:246-261.
118. Statement: NIH Discontinues Immunizations in HIV Vaccine Study. [http://www.niaid.nih.gov/news/newsreleases/2013/Pages/HVTN505April2013. aspx]. Accessed 25 April 2012.
119. Santra S, Liao HX, Zhang R, et al. Mosaic vaccines elicit CD8\+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys. Nat Med 2010; 16:324-328.
120. Letourneau S, Im EJ, Mashishi T, et al. Design and preclinical evaluation of a universal HIV-1 vaccine. PLoS One 2007; 2:e984.
121. Kulkarni V, Rosati M, Valentin A, et al. HIV-1 p24(gag) Derived Conserved Element DNA Vaccine Increases the Breadth of Immune Response in Mice. PLoS One 2013; 8:e60245.
122. van Gils MJ, Sanders RW. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology 2013; 435:46-56.